Trial Profile
A phase I/II trial of AT-307 for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs AT-307 (Primary)
- Indications Polymorphic catecholergic ventricular tachycardia
- Focus Adverse reactions; Therapeutic Use
- 16 May 2018 New trial record
- 09 May 2018 According to an Audentes Therapeutics media release, IND has been submitted for AT-307. The FDA has completed review and provided a short list of questions to be addressed prior to the IND becoming active. The company expects to submit responses in the coming weeks.